Anti-tumor effects of toxins targeted to the prostate specific membrane antigen

被引:67
作者
Fracasso, G
Bellisola, G
Cingarlini, S
Castelletti, D
Prayer-Galetti, T
Pagano, F
Tridente, G
Colombatti, M
机构
[1] Univ Verona, Policlin GB Rossi, Dept Pathol, Immunol Sect, I-37134 Verona, Italy
[2] Azienda Osped Verona, Verona, Italy
[3] Univ Padua, Dept Oncol & Surg Sci, Urol Sect, Padua, Italy
关键词
prostate carcinoma; immunotoxins; ricin; spheroids; immunotherapy; prostate-specific-membrane-antigen;
D O I
10.1002/pros.10117
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. There is presently no effective therapy for relapsing, metastatic, androgen-independent prostate cancer. Immunotherapy with monoclonal antibody-vehicled toxins (Immunotoxins, ITs) may be a promising novel treatment option for the management of prostate cancer in these cases. METHODS. Three anti-prostate specific membrane antigen (anti-PSMA) monoclonals (J591, PEQ226.5, and PM21079.1) were cross-linked to ricin A-chain (RTA; native or recombinant), and their cytotoxic effects were investigated in monolayer and three-dimensional (3-D) cell cultures of prostate carcinoma cells (LNCaP). RESULTS. The various Immunotoxins showed effects in the nanomolar range (IC50s of 1.6- 99 ng/ml) against PSMA+ cells (IC50 being the concentration inhibiting 50% cell proliferation or protein synthesis). PSMA(-) cell lines were 62- to 277-fold less sensitive to anti-PSMA ITs, evidencing an appreciable therapeutic window. Treatment with J591-smpt-nRTA (0.35-31.7ng/ml) resulted in complete eradication of 3-D tumor micromasses or in 1.46- to 0.35-log reduction of target cells number, depending on the dose. CONCLUSION. Anti-PSMA ITs appear to be promising for use in the eradication of small prostate tumor cell aggregates present in tissues and in the bone marrow. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:9 / 23
页数:15
相关论文
共 59 条
  • [21] Frankel AE, 2000, CLIN CANCER RES, V6, P326
  • [22] Frankel AE, 1996, CANCER RES, V56, P926
  • [23] FUJIMORI K, 1990, J NUCL MED, V31, P1191
  • [24] FUJIMORI K, 1989, CANCER RES, V49, P5656
  • [25] Grauer LS, 1998, CANCER RES, V58, P4787
  • [27] HOROSZEWICZ JS, 1987, ANTICANCER RES, V7, P927
  • [28] Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation
    Hu, RG
    Zhai, QW
    He, WJ
    Mei, L
    Liu, WY
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (04) : 396 - 402
  • [29] ISRAELI RS, 1994, CANCER RES, V54, P1807
  • [30] STRUCTURES OF SUGAR CHAINS OF RICIN-D
    KIMURA, Y
    HASE, S
    KOBAYASHI, Y
    KYOGOKU, Y
    IKENAKA, T
    FUNATSU, G
    [J]. JOURNAL OF BIOCHEMISTRY, 1988, 103 (06) : 944 - 949